197 related articles for article (PubMed ID: 10480438)
1. Correction of peripheral lysosomal accumulation in mice with aspartylglucosaminuria by bone marrow transplantation.
Laine M; Richter J; Fahlman C; Rapola J; Renlund M; Peltonen L; Karlsson S; Jalanko A
Exp Hematol; 1999 Sep; 27(9):1467-74. PubMed ID: 10480438
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse.
Peltola M; Kyttälä A; Heinonen O; Rapola J; Paunio T; Revah F; Peltonen L; Jalanko A
Gene Ther; 1998 Oct; 5(10):1314-21. PubMed ID: 9930336
[TBL] [Abstract][Full Text] [Related]
3. Mice with an aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in patients.
Jalanko A; Tenhunen K; McKinney CE; LaMarca ME; Rapola J; Autti T; Joensuu R; Manninen T; Sipilä I; Ikonen S; Riekkinen P; Ginns EI; Peltonen L
Hum Mol Genet; 1998 Feb; 7(2):265-72. PubMed ID: 9425233
[TBL] [Abstract][Full Text] [Related]
4. Use of nonviral promoters in adenovirus-mediated gene therapy: reduction of lysosomal storage in the aspartylglucosaminuria mouse.
Virta S; Rapola J; Jalanko A; Laine M
J Gene Med; 2006 Jun; 8(6):699-706. PubMed ID: 16518877
[TBL] [Abstract][Full Text] [Related]
5. Two novel mutations in a Canadian family with aspartylglucosaminuria and early outcome post bone marrow transplantation.
Laitinen A; Hietala M; Haworth JC; Schroeder ML; Seargeant LE; Greenberg CR; Aula P
Clin Genet; 1997 Mar; 51(3):174-8. PubMed ID: 9137882
[TBL] [Abstract][Full Text] [Related]
6. Aspartylglycosaminuria: a review.
Arvio M; Mononen I
Orphanet J Rare Dis; 2016 Dec; 11(1):162. PubMed ID: 27906067
[TBL] [Abstract][Full Text] [Related]
7. Progressive neurodegeneration in aspartylglycosaminuria mice.
Gonzalez-Gomez I; Mononen I; Heisterkamp N; Groffen J; Kaartinen V
Am J Pathol; 1998 Oct; 153(4):1293-300. PubMed ID: 9777961
[TBL] [Abstract][Full Text] [Related]
8. Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria.
Arvio P; Arvio M; Kero M; Pirinen S; Lukinmaa PL
J Med Genet; 1999 May; 36(5):398-404. PubMed ID: 10353787
[TBL] [Abstract][Full Text] [Related]
9. Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer.
Enomaa N; Danos O; Peltonen L; Jalanko A
Hum Gene Ther; 1995 Jun; 6(6):723-31. PubMed ID: 7548272
[TBL] [Abstract][Full Text] [Related]
10. Dissection of the molecular pathology of aspartylglucosaminuria provides the basis for DNA diagnostics and future therapeutic interventions.
Ikonen E; Syvänen AC; Peltonen L
Scand J Clin Lab Invest Suppl; 1993; 213():19-27. PubMed ID: 8322015
[TBL] [Abstract][Full Text] [Related]
11. A mouse model for the human lysosomal disease aspartylglycosaminuria.
Kaartinen V; Mononen I; Voncken JW; Noronkoski T; Gonzalez-Gomez I; Heisterkamp N; Groffen J
Nat Med; 1996 Dec; 2(12):1375-8. PubMed ID: 8946839
[TBL] [Abstract][Full Text] [Related]
12. Monitoring the CNS pathology in aspartylglucosaminuria mice.
Tenhunen K; Uusitalo A; Autti T; Joensuu R; Kettunen M; Kauppinen RA; Ikonen S; LaMarca ME; Haltia M; Ginns EI; Jalanko A; Peltonen L
J Neuropathol Exp Neurol; 1998 Dec; 57(12):1154-63. PubMed ID: 9862638
[TBL] [Abstract][Full Text] [Related]
13. Mutations causing aspartylglucosaminuria (AGU): a lysosomal accumulation disease.
Ikonen E; Peltonen L
Hum Mutat; 1992; 1(5):361-5. PubMed ID: 1301945
[TBL] [Abstract][Full Text] [Related]
14. Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice.
Dunder U; Valtonen P; Kelo E; Mononen I
J Inherit Metab Dis; 2010 Oct; 33(5):611-7. PubMed ID: 20607610
[TBL] [Abstract][Full Text] [Related]
15. [A family with two children diagnosed with aspartylglucosaminuria-case report and literature review].
Liu Y; Zou L; Meng Y; Zhang Y; Shi X; Ju J; Yang G; Hu L; Chen X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):455-9. PubMed ID: 25190167
[TBL] [Abstract][Full Text] [Related]
16. A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase.
Saarela J; von Schantz C; Peltonen L; Jalanko A
Hum Mutat; 2004 Oct; 24(4):350-1. PubMed ID: 15365992
[TBL] [Abstract][Full Text] [Related]
17. Expression of aspartylglucosaminidase in human tissues from normal individuals and aspartylglucosaminuria patients.
Enomaa NE; Lukinmaa PL; Ikonen EM; Waltimo JC; Palotie A; Paetau AE; Peltonen L
J Histochem Cytochem; 1993 Jul; 41(7):981-9. PubMed ID: 7685790
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria.
Dunder U; Kaartinen V; Valtonen P; Väänänen E; Kosma VM; Heisterkamp N; Groffen J; Mononen I
FASEB J; 2000 Feb; 14(2):361-7. PubMed ID: 10657992
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations.
Saarela J; Laine M; Oinonen C; von Schantz C; Jalanko A; Rouvinen J; Peltonen L
Hum Mol Genet; 2001 Apr; 10(9):983-95. PubMed ID: 11309371
[TBL] [Abstract][Full Text] [Related]
20. Aspartylglycosaminuria: biochemistry and molecular biology.
Aronson NN
Biochim Biophys Acta; 1999 Oct; 1455(2-3):139-54. PubMed ID: 10571008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
